Mesothelioma Clinical Trials

99 recruitingLast updated: June 17, 2026

There are 99 actively recruiting mesothelioma clinical trials across 27 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3. Top locations include Houston, Texas, United States, Chicago, Illinois, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Mesothelioma Trials at a Glance

99 actively recruiting trials for mesothelioma are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 1 with 39 trials, with the heaviest enrollment activity in Houston, Chicago, and New York. Lead sponsors running mesothelioma studies include National Cancer Institute (NCI), Memorial Sloan Kettering Cancer Center, and A2 Biotherapeutics Inc..

Browse mesothelioma trials by phase

Treatments under study

About Mesothelioma Clinical Trials

Looking for clinical trials for Mesothelioma? There are currently 47 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Mesothelioma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Mesothelioma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 99 trials

Recruiting

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

Thoracic CancersLung Cancer NOSMalignant Pleural Mesotheliomas NOS+2 more
National Cancer Institute (NCI)1,559 enrolled1 locationNCT00242723
Recruiting

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

Familial CancerMesotheliomaBRCA1-Associated Protein-1 (BAP1) Mutations+1 more
National Cancer Institute (NCI)300 enrolled1 locationNCT04431024
Recruiting

Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1

MesotheliomaFamilies
National Cancer Institute (NCI)1,000 enrolled1 locationNCT03830229
Recruiting
Phase 1

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Ovarian NeoplasmsStomach NeoplasmsLung Neoplasms+5 more
National Cancer Institute (NCI)100 enrolled1 locationNCT06885697
Recruiting
Not Applicable

PTC-Guided Therapy for Peritoneal Mesothelioma

Peritoneal Mesothelioma
Beijing Tsinghua Chang Gung Hospital347 enrolled1 locationNCT07330271
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Colorectal, CancerOvarian CancerLung Cancer+17 more
A2 Biotherapeutics Inc.474 enrolled12 locationsNCT06051695
Recruiting
Phase 1

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Colorectal, CancerMesothelin-Expressing TumorsEpithelial Ovarian Cancer+8 more
Context Therapeutics Inc.70 enrolled9 locationsNCT06756035
Recruiting
Phase 1

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Gastric Adenocarcinoma+10 more
IDEAYA Biosciences260 enrolled12 locationsNCT07277413
Recruiting

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

Stomach NeoplasmsMesotheliomaPancreatic Neoplasms+3 more
National Cancer Institute (NCI)1,000 enrolled1 locationNCT01950572
Recruiting
Phase 1Phase 2

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma
University Hospital, Antwerp15 enrolled3 locationsNCT05765084
Recruiting
Phase 1Phase 2

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Colorectal, CancerEsophageal CancerGastric Cancer+5 more
Perspective Therapeutics112 enrolled8 locationsNCT06710756
Recruiting
Phase 2

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Peritoneal Malignant Mesothelioma
National Cancer Institute (NCI)66 enrolled40 locationsNCT05001880
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 2

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Pleural Biphasic MesotheliomaPleural Sarcomatoid Mesothelioma
Alliance for Clinical Trials in Oncology26 enrolled132 locationsNCT05647265
Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Colorectal, CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+14 more
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting
Phase 2

A Study of Sacituzumab Govitecan in People With Mesothelioma

MesotheliomaMesotheliomas PleuralMesothelioma; Pleura
Memorial Sloan Kettering Cancer Center33 enrolled7 locationsNCT06477419
Recruiting
Phase 2

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)+2 more
AstraZeneca257 enrolled95 locationsNCT06535607
Recruiting
Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Phase 2

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

Malignant MesotheliomaCD30-Positive Neoplastic Cells Present
M.D. Anderson Cancer Center55 enrolled1 locationNCT03007030
Recruiting
Phase 1

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Ovarian CancerMesothelioma, MalignantCholangiocarcinoma Recurrent
Verismo Therapeutics42 enrolled5 locationsNCT05568680